ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Texas » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Texas

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
MOUNIR BORNO M.D.

Cardiovascular Disease

20,834

$1.08M

1304
1172 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 27%

$52
Average prescription price

Avg: $64

AYMAN KARKOUTLY M.D.

Cardiovascular Disease

17,706

$1.27M

680
553 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

9%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 27%

$72
Average prescription price

Avg: $64

JOAQUIN MARTINEZ-ARRARAS M.D.

Cardiovascular Disease

17,698

$1.24M

810
725 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 27%

$70
Average prescription price

Avg: $64

ROBERTO SOLIS M.D.

Cardiovascular Disease

16,788

$917K

1080
970 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 27%

$55
Average prescription price

Avg: $64

DONALD WURZBURG MD

Cardiovascular Disease

16,783

$785K

1228
977 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 27%

$47
Average prescription price

Avg: $64

JAIME SILVA MD

Cardiovascular Disease

16,667

$1.46M

1251
1093 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 1%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 27%

$88
Average prescription price

Avg: $64

MANISH SHROFF M.D.

Cardiovascular Disease

15,836

$794K

630
454 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

27%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 27%

$50
Average prescription price

Avg: $64

AGUSTIN CABRERA-SANTAMARIA M.D.

Cardiovascular Disease

15,238

$888K

932
798 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 27%

$58
Average prescription price

Avg: $64

ROBERT SWEET M.D.

Cardiovascular Disease

14,754

$885K

1152
1054 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 27%

$60
Average prescription price

Avg: $64

M SHARIF M.D.

Cardiovascular Disease

14,316

$810K

899
807 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 27%

$57
Average prescription price

Avg: $64

MOHAMMAD SHOUKFEH M.D.

Cardiovascular Disease

14,081

$925K

817
737 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 27%

$66
Average prescription price

Avg: $64

KHALID SHAFIQ MD, FACC, FSCAI

Cardiovascular Disease

13,921

$527K

976
779 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 27%

$38
Average prescription price

Avg: $64

TIMOTHY COLGAN M.D.

Cardiovascular Disease

13,678

$870K

977
837 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 27%

$64
Average prescription price

Avg: $64

JAMIL BITAR M.D.

Cardiovascular Disease

13,575

$652K

760
634 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 27%

$48
Average prescription price

Avg: $64

JOEL OSBORN M.D.

Cardiovascular Disease

13,427

$645K

904
844 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 27%

$48
Average prescription price

Avg: $64

RODOLFO SOTOLONGO MD

Cardiovascular Disease

13,384

$745K

1147
970 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 27%

$56
Average prescription price

Avg: $64

DEVENDER REDDY M.D.

Cardiovascular Disease

12,720

$706K

431
370 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 27%

$55
Average prescription price

Avg: $64

RAJA NAIDU MD

Cardiovascular Disease

12,207

$703K

770
641 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

16%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 27%

$58
Average prescription price

Avg: $64

MADJID MIRZAITEHRANE MD

Cardiovascular Disease

12,179

$594K

952
835 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 27%

$49
Average prescription price

Avg: $64

WALTER BROGAN MD

Cardiovascular Disease

11,955

$623K

919
855 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 27%

$52
Average prescription price

Avg: $64

D SOYA M.D.

Cardiovascular Disease

11,883

$418K

844
753 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 27%

$35
Average prescription price

Avg: $64

ROBERT MCFARLANE M.D.

Cardiovascular Disease

11,847

$696K

420
303 are 65+

4%
patients receiving schedule two controlled substances

Avg: 0%

24%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 27%

$59
Average prescription price

Avg: $64

ROBERTO ROBLES MD

Cardiovascular Disease

11,612

$532K

877
767 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 27%

$46
Average prescription price

Avg: $64

MICHAEL MILLER MD

Cardiovascular Disease

11,612

$723K

699
651 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 27%

$62
Average prescription price

Avg: $64

JOHN ZIAS MD

Cardiovascular Disease

11,483

$576K

648
582 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 27%

$50
Average prescription price

Avg: $64

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank